M

MacroGenics
D

MGNX

2.76000
USD
-0.13
(-4.50%)
مغلق
حجم التداول
27,345
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
173,227,116
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARRY
    -0.31500
    (-4.57%)
    6.58500 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NKTR
    -0.02600
    (-2.72%)
    0.93130 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    X
    XNCR
    -0.030
    (-0.19%)
    15.740 USD
    المزيد
الأخبار
المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).